ViaNautis Bio announces a collaboration with Eli Lilly (LLY) and Company. Under the terms of the agreement, ViaNautis will receive an initial upfront payment from Lilly, with the short-term potential for additional payments including research-based milestones. Further milestones and royalties would be due should specific cargo-loaded polyNaut-based products enter the clinic and reach commercialisation. This collaboration will leverage ViaNautis’ platform for precise delivery of genetic cargos to prioritised tissues to address significant unmet medical needs. ViaNautis’ proprietary polyNaut nanovesicles are designed to deliver genetic materials with precise targeting of specific tissues and cell types. This technology aims to improve current genetic medicine delivery, potentially transforming treatment options for various diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024
- Apogee Therapeutics price target raised to $100 from $81 at BTIG
- Eli Lilly’s Weight Loss Drug Mounjaro Finds its Place in Hong Kong
- Eli Lilly announces results from two, multi-year mirikizumab studies
- LLY Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
